Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study

Objective: Mitotane is the standard therapy for advanced pediatric adrenocortical carcinoma (pACC). With improving survival, treatment-related long-term side effects and their impact on everyday functioning are becoming increasingly relevant. This multicenter pilot study provides first insights into...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Heidi Frey, Maria Riedmeier, Johanna Krüger, Carl Friedrich Classen, Nerea Domínguez-Pinilla, Maria Fragoso, Steffen Fuchs, Dominika Janus, Mouna Mezoued, Andrea Mocna, Jessica Munarin, Soraya Puglisi, Hilal Susam Sen, Gerdi Tuli, Justyna Walenciak, Bilgehan Yalcin, Martin Fassnacht, Verena Wiegering
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Bioscientifica 2026-06-01
Rangatū:	Endocrine Oncology
Ngā marau:	pediatric adrenocortical carcinoma pediatric adrenocortical tumor mitotane adverse side effects neuropsychological long-term outcome
Urunga tuihono:	https://eo.bioscientifica.com/view/journals/eo/6/1/EO-26-0010.xml
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study

Ngā tūemi rite